OBJECTIVES: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM). METHODS: INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA-IXA, and REMIX. RESULTS: Overall, 391/100/68 were lenalidomide-naïve/-exposed/-refractory and 37/411/110 were PI-naïve/-exposed/-refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression-free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide-naïve/exposed/refractory patients. Median DOT and PFS in PI-naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide-naïve/exposed/refractory patients in INSIGHT and UVEA-IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI-naïve/exposed/refractory patients in INSIGHT and UVEA-IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable. CONCLUSION: IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide- and/or PI-nonrefractory versus refractory patients.

CHU de Caen Normandie Caen France

Clinica São Germano and Santa Casa Medical School São Paulo Brazil

Department of Haematology Oxford University Hospitals NHS Foundation Trust Oxford Oxfordshire UK

Department of Lymphoma Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA

Hematology Department Hospital Universitario de Salamanca CIBERONC Salamanca Spain

Indiana University School of Medicine Indianapolis Indiana USA

Institute of Biostatistics and Analyses Ltd Brno Czech Republic

Perlmutter Cancer Center NYU Langone New York City New York USA

Pôle Régional de Cancérologie Department of Hematology CHU La Milétrie Poitiers Poitiers France

Takeda Development Center Americas Inc Lexington Massachusetts USA

Takeda Pharmaceuticals U S A Inc Lexington Massachusetts USA

University of Arkansas for Medical Sciences Little Rock Arkansas USA

See more in PubMed

NINLARO. US Prescribing Information. NINLARO; 2022 Accessed January 2023. https://www.ninlaro.com/prescribing-information.pdf

European Medicines Agency. Summary of Product Characteristics. European Medicines Agency; 2023 Accessed February 2024. https://www.ema.europa.eu/en/documents/product‐information/ninlaro‐epar‐product‐information_en.pdf

Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621‐1634.

Puig N, Abonour R, Davies FE, et al. Real‐world duration of treatment (DOT) with lenalidomide‐dexamethasone (rd)‐based regimens in patients (pts) with relapsed/refractory multiple myeloma (RRMM): outcomes from the global INSIGHT MM study. HemaSphere. 2021;5(Suppl 2):463.

Ludwig H, Terpos E, Mateos M‐V, et al. Effectiveness and safety of ixazomib‐based therapy in relapsed/refractory multiple myeloma (MM) outside of a clinical trial: final analysis of the ‘use via early access to ixazomib’ (UVEA IXA) study. HemaSphere. 2021;5(Suppl 2):468.

Macro M, Hulin C, Vincent L, et al. Real‐world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study. Ann Hematol. 2023;102(8):2137‐2151.

Leleu X, Lee HC, Zonder JA, et al. INSURE: a pooled analysis of ixazomib‐lenalidomide‐dexamethasone for relapsed/refractory myeloma in routine practice. Future Oncol. 2024;20(14):935‐950.

Hajek R, Minarik J, Straub J, et al. Ixazomib‐lenalidomide‐dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021;17(19):2499‐2512.

Terpos E, Ramasamy K, Maouche N, et al. Real‐world effectiveness and safety of ixazomib‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma. Ann Hematol. 2020;99(5):1049‐1061.

Minarik J, Pika T, Radocha J, et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021;21(1):73.

Lee JH, Kim SH, Kim HR, et al. Real‐world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma. Int J Hematol. 2023;117(2):225‐235.

Minarik J, Radocha J, Jungova A, et al. Ixazomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma in routine clinical practice: extended follow‐up analysis and the results of subsequent therapy. Cancers (Basel). 2022;14(20):5165.

Maouche N, Kishore B, Jenner MW, et al. Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience. Leuk Lymphoma. 2021;62(6):1396‐1404.

Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10(9):94.

Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow‐up of POLLUX, a randomized, open‐label, phase 3 study. Leukemia. 2020;34(7):1875‐1884.

Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real‐world setting. Blood Cancer J. 2018;8(11):109.

Chari A, Romanus D, Palumbo A, et al. Randomized clinical trial representativeness and outcomes in real‐world patients: comparison of 6 hallmark randomized clinical trials of relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):8‐17.e16.

Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical‐trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021;11(2):40.

Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib‐lenalidomide‐dexamethasone vs. placebo‐lenalidomide‐dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE‐MM1. Haematologica. 2017;102(10):1767‐1775.

Ding K, Yu H, Shao YY, et al. Real‐world data on the efficacy and safety of ixazomib‐based therapy in multiple myeloma: a single‐center study in China. Cancer Manag Res. 2020;12:8935‐8941.

Botta C, Martino EA, Conticello C, et al. Treatment of lenalidomide exposed or refractory multiple myeloma: network meta‐analysis of lenalidomide‐sparing regimens. Front Oncol. 2021;11:643490.

Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA‐ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32(3):309‐322.

Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE‐MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430‐2442.

Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open‐label, phase 3 study. Lancet. 2020;396(10245):186‐197.

Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open‐label, randomised phase 3 trial. Lancet. 2021;397(10292):2361‐2371.

Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301‐313.

Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132‐147.

Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495‐505.

Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B‐cell maturation antigen‐directed chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE‐1): a phase 1b/2 open‐label study. Lancet. 2021;398(10297):314‐324.

Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705‐716.